DK175363B1 - Fremgangsmåde til kontinuert produktion af et önsket heterologt protein i en eukaryotisk værtcelle, vektor, som tilförer denne evne, og celler transformeret med vektoren - Google Patents

Fremgangsmåde til kontinuert produktion af et önsket heterologt protein i en eukaryotisk værtcelle, vektor, som tilförer denne evne, og celler transformeret med vektoren Download PDF

Info

Publication number: DK175363B1
Authority: DK; Denmark
Prior art keywords: sequence; vector; cells; factor viii; expression
Prior art date: 1986-09-12

Application number

DK473987A

Other languages

Danish (da)

English (en)

Other versions

DK473987D0 (da

DK473987A (da

Inventor

Cornelia Maxine Gorman

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-09-12

Filing date

1987-09-11

Publication date

2004-09-13

1987-09-11 Application filed by Genentech Inc filed Critical Genentech Inc

1987-09-11 Publication of DK473987D0 publication Critical patent/DK473987D0/da

1988-03-13 Publication of DK473987A publication Critical patent/DK473987A/da

2004-09-13 Application granted granted Critical

2004-09-13 Publication of DK175363B1 publication Critical patent/DK175363B1/da

Links

108090000623 proteins and genes Proteins 0.000 title claims description 139
239000013598 vector Substances 0.000 title claims description 89
102000004169 proteins and genes Human genes 0.000 title claims description 82
238000000034 method Methods 0.000 title claims description 45
238000010924 continuous production Methods 0.000 title claims description 15
230000008569 process Effects 0.000 title description 4
210000004027 cell Anatomy 0.000 claims description 242
108010054218 Factor VIII Proteins 0.000 claims description 137
102000001690 Factor VIII Human genes 0.000 claims description 135
229960000301 factor viii Drugs 0.000 claims description 132
230000014509 gene expression Effects 0.000 claims description 60
239000013604 expression vector Substances 0.000 claims description 47
108020004999 messenger RNA Proteins 0.000 claims description 41
239000003623 enhancer Substances 0.000 claims description 39
230000008488 polyadenylation Effects 0.000 claims description 37
238000001890 transfection Methods 0.000 claims description 28
230000000087 stabilizing effect Effects 0.000 claims description 25
239000002773 nucleotide Substances 0.000 claims description 21
125000003729 nucleotide group Chemical group 0.000 claims description 21
108020004414 DNA Proteins 0.000 claims description 16
108010087851 prorelaxin Proteins 0.000 claims description 15
230000005030 transcription termination Effects 0.000 claims description 10
241000282693 Cercopithecidae Species 0.000 claims description 9
241000701024 Human betaherpesvirus 5 Species 0.000 claims description 8
101800004937 Protein C Proteins 0.000 claims description 8
101800001700 Saposin-D Proteins 0.000 claims description 8
229960000856 protein c Drugs 0.000 claims description 8
241000700605 Viruses Species 0.000 claims description 7
210000003527 eukaryotic cell Anatomy 0.000 claims description 7
238000003776 cleavage reaction Methods 0.000 claims description 6
210000003292 kidney cell Anatomy 0.000 claims description 6
230000007017 scission Effects 0.000 claims description 6
102000053602 DNA Human genes 0.000 claims description 3
238000004113 cell culture Methods 0.000 claims description 3
206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
210000000717 sertoli cell Anatomy 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 9
108700002232 Immediate-Early Genes Proteins 0.000 claims 4
102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 claims 1
230000002349 favourable effect Effects 0.000 claims 1
239000012634 fragment Substances 0.000 description 76
235000018102 proteins Nutrition 0.000 description 66
239000013612 plasmid Substances 0.000 description 52
108020004635 Complementary DNA Proteins 0.000 description 49
239000002299 complementary DNA Substances 0.000 description 39
108010022394 Threonine synthase Proteins 0.000 description 30
102000004419 dihydrofolate reductase Human genes 0.000 description 30
238000004519 manufacturing process Methods 0.000 description 30
239000002609 medium Substances 0.000 description 28
241000701022 Cytomegalovirus Species 0.000 description 27
230000004927 fusion Effects 0.000 description 22
238000010276 construction Methods 0.000 description 21
230000010474 transient expression Effects 0.000 description 21
108050006955 Tissue-type plasminogen activator Proteins 0.000 description 20
108020001507 fusion proteins Proteins 0.000 description 20
230000035897 transcription Effects 0.000 description 20
238000013518 transcription Methods 0.000 description 20
102100033571 Tissue-type plasminogen activator Human genes 0.000 description 19
102000037865 fusion proteins Human genes 0.000 description 19
238000010186 staining Methods 0.000 description 19
210000004978 chinese hamster ovary cell Anatomy 0.000 description 16
230000000694 effects Effects 0.000 description 16
230000015271 coagulation Effects 0.000 description 14
238000005345 coagulation Methods 0.000 description 14
108091092195 Intron Proteins 0.000 description 13
108020005067 RNA Splice Sites Proteins 0.000 description 13
230000003321 amplification Effects 0.000 description 13
238000003199 nucleic acid amplification method Methods 0.000 description 13
102000004594 DNA Polymerase I Human genes 0.000 description 12
108010017826 DNA Polymerase I Proteins 0.000 description 12
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 12
229960000485 methotrexate Drugs 0.000 description 12
230000010473 stable expression Effects 0.000 description 12
108010090955 preprorelaxin Proteins 0.000 description 11
241000701161 unidentified adenovirus Species 0.000 description 11
229960001134 von willebrand factor Drugs 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
238000004458 analytical method Methods 0.000 description 10
230000001052 transient effect Effects 0.000 description 10
108010047303 von Willebrand Factor Proteins 0.000 description 10
108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
239000000427 antigen Substances 0.000 description 9
108091007433 antigens Proteins 0.000 description 9
102000036639 antigens Human genes 0.000 description 9
208000006454 hepatitis Diseases 0.000 description 9
231100000283 hepatitis Toxicity 0.000 description 9
238000012360 testing method Methods 0.000 description 9
108091028043 Nucleic acid sequence Proteins 0.000 description 8
241000283973 Oryctolagus cuniculus Species 0.000 description 8
239000007983 Tris buffer Substances 0.000 description 8
230000015556 catabolic process Effects 0.000 description 8
238000006731 degradation reaction Methods 0.000 description 8
230000002787 reinforcement Effects 0.000 description 8
230000010076 replication Effects 0.000 description 8
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
102000017975 Protein C Human genes 0.000 description 7
150000001413 amino acids Chemical group 0.000 description 7
229960000723 ampicillin Drugs 0.000 description 7
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 7
239000000872 buffer Substances 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
239000003550 marker Substances 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
235000001014 amino acid Nutrition 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
230000012010 growth Effects 0.000 description 6
108091008146 restriction endonucleases Proteins 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
108091035707 Consensus sequence Proteins 0.000 description 5
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 5
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 5
229930193140 Neomycin Natural products 0.000 description 5
108020005091 Replication Origin Proteins 0.000 description 5
230000001580 bacterial effect Effects 0.000 description 5
239000000701 coagulant Substances 0.000 description 5
239000000499 gel Substances 0.000 description 5
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 5
238000011534 incubation Methods 0.000 description 5
229960004927 neomycin Drugs 0.000 description 5
150000007523 nucleic acids Chemical class 0.000 description 5
239000002244 precipitate Substances 0.000 description 5
230000006641 stabilisation Effects 0.000 description 5
238000011105 stabilization Methods 0.000 description 5
230000009466 transformation Effects 0.000 description 5
JRBJSXQPQWSCCF-UHFFFAOYSA-N 3,3'-Dimethoxybenzidine Chemical compound C1=C(N)C(OC)=CC(C=2C=C(OC)C(N)=CC=2)=C1 JRBJSXQPQWSCCF-UHFFFAOYSA-N 0.000 description 4
241000972773 Aulopiformes Species 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 4
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
108090000190 Thrombin Proteins 0.000 description 4
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 4
239000001110 calcium chloride Substances 0.000 description 4
235000011148 calcium chloride Nutrition 0.000 description 4
229910001628 calcium chloride Inorganic materials 0.000 description 4
230000001086 cytosolic effect Effects 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
239000012894 fetal calf serum Substances 0.000 description 4
102000057593 human F8 Human genes 0.000 description 4
229960000900 human factor viii Drugs 0.000 description 4
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
210000004962 mammalian cell Anatomy 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
108020004707 nucleic acids Proteins 0.000 description 4
102000039446 nucleic acids Human genes 0.000 description 4
238000012545 processing Methods 0.000 description 4
235000019515 salmon Nutrition 0.000 description 4
238000012216 screening Methods 0.000 description 4
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
239000000758 substrate Substances 0.000 description 4
229960004072 thrombin Drugs 0.000 description 4
239000013603 viral vector Substances 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
239000004475 Arginine Substances 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
108700024394 Exon Proteins 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
239000000020 Nitrocellulose Substances 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
108091036066 Three prime untranslated region Proteins 0.000 description 3
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000011575 calcium Substances 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
239000004927 clay Substances 0.000 description 3
230000001143 conditioned effect Effects 0.000 description 3
238000005520 cutting process Methods 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
229920001220 nitrocellulos Polymers 0.000 description 3
210000004940 nucleus Anatomy 0.000 description 3
235000015097 nutrients Nutrition 0.000 description 3
239000012679 serum free medium Substances 0.000 description 3
230000035939 shock Effects 0.000 description 3
210000002435 tendon Anatomy 0.000 description 3
230000002103 transcriptional effect Effects 0.000 description 3
230000014616 translation Effects 0.000 description 3
102100034613 Annexin A2 Human genes 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
101150074155 DHFR gene Proteins 0.000 description 2
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
241000206602 Eukaryota Species 0.000 description 2
108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
108091092724 Noncoding DNA Proteins 0.000 description 2
102000003992 Peroxidases Human genes 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
108090000103 Relaxin Proteins 0.000 description 2
101150003725 TK gene Proteins 0.000 description 2
108700009124 Transcription Initiation Site Proteins 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000004913 activation Effects 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
238000003556 assay Methods 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
239000013611 chromosomal DNA Substances 0.000 description 2
230000002759 chromosomal effect Effects 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
230000030609 dephosphorylation Effects 0.000 description 2
238000006209 dephosphorylation reaction Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
230000029087 digestion Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
-1 e.g. Proteins 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000010354 integration Effects 0.000 description 2
210000005229 liver cell Anatomy 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
230000011987 methylation Effects 0.000 description 2
238000007069 methylation reaction Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000037361 pathway Effects 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
230000006337 proteolytic cleavage Effects 0.000 description 2
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000007447 staining method Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
238000012546 transfer Methods 0.000 description 2
238000013519 translation Methods 0.000 description 2
NWXMGUDVXFXRIG-NAOJVREFSA-N (4s,4as,5as,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2C(O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-NAOJVREFSA-N 0.000 description 1
DJMUYABFXCIYSC-UHFFFAOYSA-N 1H-phosphole Chemical compound C=1C=CPC=1 DJMUYABFXCIYSC-UHFFFAOYSA-N 0.000 description 1
CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
101150110188 30 gene Proteins 0.000 description 1
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
108020003589 5' Untranslated Regions Proteins 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
102100023635 Alpha-fetoprotein Human genes 0.000 description 1
108090000668 Annexin A2 Proteins 0.000 description 1
108700003860 Bacterial Genes Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
101000983057 Bothrops brazili Basic phospholipase A2 myotoxin-I Proteins 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
101000685088 Buthus occitanus tunetanus Alpha-toxin Bot1 Proteins 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282465 Canis Species 0.000 description 1
108090000565 Capsid Proteins Proteins 0.000 description 1
102100023321 Ceruloplasmin Human genes 0.000 description 1
108091062157 Cis-regulatory element Proteins 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
101100346656 Drosophila melanogaster strat gene Proteins 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
108060002716 Exonuclease Proteins 0.000 description 1
108010014172 Factor V Proteins 0.000 description 1
241000233866 Fungi Species 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
101710154606 Hemagglutinin Proteins 0.000 description 1
208000031220 Hemophilia Diseases 0.000 description 1
208000009292 Hemophilia A Diseases 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
101001130226 Homo sapiens Phosphatidylcholine-sterol acyltransferase Proteins 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108010067372 Pancreatic elastase Proteins 0.000 description 1
102000016387 Pancreatic elastase Human genes 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
102000001938 Plasminogen Activators Human genes 0.000 description 1
108010001014 Plasminogen Activators Proteins 0.000 description 1
101710176177 Protein A56 Proteins 0.000 description 1
230000006819 RNA synthesis Effects 0.000 description 1
102000003743 Relaxin Human genes 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
241000030538 Thecla Species 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
108091061763 Triple-stranded DNA Proteins 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
230000006154 adenylylation Effects 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
108010026331 alpha-Fetoproteins Proteins 0.000 description 1
229910052787 antimony Inorganic materials 0.000 description 1
WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
238000000429 assembly Methods 0.000 description 1
230000000712 assembly Effects 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
208000019065 cervical carcinoma Diseases 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
230000035602 clotting Effects 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
239000004020 conductor Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
239000003398 denaturant Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
229940079919 digestives enzyme preparation Drugs 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
102000013165 exonuclease Human genes 0.000 description 1
230000001036 exonucleolytic effect Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000007429 general method Methods 0.000 description 1
108060003196 globin Proteins 0.000 description 1
102000018146 globin Human genes 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000000185 hemagglutinin Substances 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
102000055277 human IL2 Human genes 0.000 description 1
102000053852 human LCAT Human genes 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
238000007654 immersion Methods 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000009413 insulation Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000004853 protein function Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
241000894007 species Species 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
230000001502 supplementing effect Effects 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
235000008979 vitamin B4 Nutrition 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000001262 western blot Methods 0.000 description 1
239000002023 wood Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/64—Relaxins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Microbiology (AREA)
Medicinal Chemistry (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Endocrinology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK473987A 1986-09-12 1987-09-11 Fremgangsmåde til kontinuert produktion af et önsket heterologt protein i en eukaryotisk værtcelle, vektor, som tilförer denne evne, og celler transformeret med vektoren DK175363B1 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US90718586A	1986-09-12	1986-09-12
US90718586		1986-09-12
US7167487A	1987-07-09	1987-07-09
US7167487		1987-07-09

Publications (3)

Publication Number	Publication Date
DK473987D0 DK473987D0 (da)	1987-09-11
DK473987A DK473987A (da)	1988-03-13
DK175363B1 true DK175363B1 (da)	2004-09-13

Family

ID=26752513

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK473987A DK175363B1 (da)	1986-09-12	1987-09-11	Fremgangsmåde til kontinuert produktion af et önsket heterologt protein i en eukaryotisk værtcelle, vektor, som tilförer denne evne, og celler transformeret med vektoren

Country Status (9)

Country	Link
EP (1)	EP0260148A3 (fr)
JP (3)	JP2888518B2 (fr)
AU (1)	AU613316B2 (fr)
DE (1)	DE3730599A1 (fr)
DK (1)	DK175363B1 (fr)
FR (1)	FR2603899B1 (fr)
GB (1)	GB2197321B (fr)
IE (1)	IE872455L (fr)
NZ (1)	NZ221790A (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1341482C (fr) *	1984-10-31	2005-05-10	Paul A. Luciw	Procede de preparation de fragments de retrovirus du groupe du sida
DE3545126A1 (de) *	1985-12-19	1987-06-25	Boehringer Mannheim Gmbh	Verfahren zur verbesserung der expression von eukaryontenprotein
AU613876B2 (en) *	1986-10-01	1991-08-15	Merck & Co., Inc.	Synthetic genes encoding proteins from plasmid containing eucaryotic secretory signal peptides and process for secreting encoded proteins
US5024939A (en) *	1987-07-09	1991-06-18	Genentech, Inc.	Transient expression system for producing recombinant protein
GB8717430D0 (en) *	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
EP0967277A3 (fr) *	1988-09-06	2003-10-15	Xoma Corporation	Production d' anticorps chimèriques murins/humains contre des antigènes de tumeurs humains
US5576184A (en) *	1988-09-06	1996-11-19	Xoma Corporation	Production of chimeric mouse-human antibodies with specificity to human tumor antigens
ATE128730T1 (de) *	1988-12-13	1995-10-15	Univ Harvard	Prototypische felv-isolate für die verwendung als krankheitsmuster oder impfstoffe.
JPH02261386A (ja) *	1989-03-31	1990-10-24	Kyowa Hakko Kogyo Co Ltd	組換えベクター
WO1990013659A1 (fr) *	1989-05-04	1990-11-15	Genentech, Inc.	Procedes et compositions d'isolement de la relaxine humaine
CA2018676C (fr) *	1989-06-20	2003-05-06	Christie A. Kelton	Methodes de production de proteines heteropolymeriques
SE8903865D0 (sv) *	1989-11-17	1989-11-17	Kabigen Ab	Expression of heterologous proteins using eukaryotic cells
US5633076A (en) *	1989-12-01	1997-05-27	Pharming Bv	Method of producing a transgenic bovine or transgenic bovine embryo
GB9027917D0 (en) *	1990-12-21	1991-02-13	Ici Plc	Expression systems
US6749853B1 (en)	1992-03-05	2004-06-15	Board Of Regents, The University Of Texas System	Combined methods and compositions for coagulation and tumor treatment
DE69433925T2 (de) *	1993-06-10	2005-07-28	Bayer Corp.	Vektoren und Zelllinien von Säugetieren mit erhöhter Produktivität
GB9408573D0 (en) *	1994-04-29	1994-06-22	Gatsby Charitable Foundation	Identification, production and use of saponin gylcosyl hydrolases
US5561053A (en) *	1994-08-05	1996-10-01	Genentech, Inc.	Method for selecting high-expressing host cells
US6818439B1 (en)	1994-12-30	2004-11-16	Chiron Corporation	Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
US5681746A (en) *	1994-12-30	1997-10-28	Chiron Viagene, Inc.	Retroviral delivery of full length factor VIII
WO1997046589A2 (fr)	1996-06-07	1997-12-11	Neorx Corporation	Anticorps humanises se liant au meme antigene que celui lie par l'anticorps nr-lu-13 et leur utilisation dans des procedes de preciblage
BR9806793A (pt)	1997-01-22	2000-05-16	Univ Texas	Processos e composições de fator tissular para coagulação e tratamento de tumores.
US5854021A (en) *	1997-02-28	1998-12-29	Bayer Corporation	Enhance protein production method
WO1999029848A1 (fr) *	1997-12-05	1999-06-17	The Immune Response Corporation	Vecteurs et genes a expression accrue
US6818213B1 (en)	1998-07-13	2004-11-16	Board Of Regents, The University Of Texas System	Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US7067109B1 (en)	1998-07-13	2006-06-27	Board Of Regents, The University Of Texas System	Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
US6051401A (en) *	1998-07-28	2000-04-18	Bayer Corporation	Methods and constructs for protein expression
US7399751B2 (en) *	1999-11-04	2008-07-15	Sertoli Technologies, Inc.	Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
US6358703B1 (en)	1998-12-10	2002-03-19	Bayer Corporation	Expression system for factor VIII
FR2823222B1 (fr)	2001-04-06	2004-02-06	Merial Sas	Vaccin contre le virus de la fievre du nil
MXPA05003049A (es)	2002-09-19	2005-11-17	Us Gov Health & Human Serv	Polipeptidos de phlebotomus ariasi, polipeptidos de phlebotomus perniciosus y metodos de uso.
MXPA05004714A (es)	2002-10-29	2006-03-17	Us Gov Health & Human Serv	Polipeptidos de lutzomyia longipalpis y metodos de uso.
BRPI0318114B8 (pt)	2003-02-19	2022-07-05	Merial Ltd	Vacinação ou imunização utilizando um regime de iniciação-reforço
US7468273B2 (en)	2003-05-01	2008-12-23	Meial Limited	Canine GHRH gene, polypeptides and methods of use
ES2319198T3 (es) *	2003-10-16	2009-05-05	Claude Negrier	Adnc modificado para niveles de expresion altos de factor viii y sus derivados.
PT1881845E (pt)	2005-04-25	2010-05-31	Merial Ltd	Vacinas de vírus nipah
US20080241184A1 (en)	2005-08-25	2008-10-02	Jules Maarten Minke	Canine influenza vaccines
US7771995B2 (en)	2005-11-14	2010-08-10	Merial Limited	Plasmid encoding human BMP-7
EP3147296A1 (fr)	2005-11-14	2017-03-29	Merial, Inc.	Thérapie génique pour traiter l'insuffisance rénale
NZ571459A (en)	2006-03-29	2011-09-30	Merial Ltd	Vaccine against streptococcus equi
US7862821B2 (en)	2006-06-01	2011-01-04	Merial Limited	Recombinant vaccine against bluetongue virus
UA100692C2 (ru)	2007-05-02	2013-01-25	Мериал Лимитед	Днк-плазмиды, имеющие повышенную экспрессию и стабильность
MX348137B (es)	2008-05-08	2017-05-29	Merial Ltd	Vacuna de la leishmaniasis con el uso del inmunogeno salival de la mosca de la arena.
RU2422504C2 (ru) *	2008-11-07	2011-06-27	Учреждение Российской академии наук Институт микробиологии им. С.Н. Виноградского РАН	СПОСОБ ПОЛУЧЕНИЯ ЭКСПРЕССИОННОГО ПЛАЗМИДНОГО ВЕКТОРА, ОБЛАДАЮЩЕГО ПОВЫШЕННОЙ СТАБИЛЬНОСТЬЮ НАСЛЕДОВАНИЯ В КЛЕТКАХ Escherichia coli
RU2559527C2 (ru)	2008-11-28	2015-08-10	Мериал Лимитед	Рекомбинантная вакцина от птичьего гриппа и её применение
WO2010115133A2 (fr)	2009-04-03	2010-10-07	Merial Limited	Vaccins aviaires transportés par le virus de la maladie de newcastle
RU2548809C2 (ru)	2009-05-22	2015-04-20	Мериал Лимитед	Плазмида без устойчивости к антибиотику
ES2617743T3 (es)	2010-03-12	2017-06-19	Merial, Inc.	Vacunas recombinantes del virus de la lengua azul y sus utilizaciones
WO2012030720A1 (fr)	2010-08-31	2012-03-08	Merial Limited	Vaccins contre le virus herpétique à base de vecteurs du virus de la maladie de newcastle
US9216213B2 (en)	2011-04-20	2015-12-22	Merial, Inc.	Adjuvanted rabies vaccine with improved viscosity profile
CA2837375C (fr)	2011-06-01	2019-07-16	Merial Limited	Administration sans aiguille de vaccins contre le vsrrp
SMT201900129T1 (it)	2011-07-20	2019-05-10	Centre Nat Rech Scient	Vaccino ricombinante contro il virus della leucemia felina contenente un gene ottimizzato dell'involucro del virus della leucemia felina
NZ700470A (en)	2012-03-20	2016-04-29	Merial Inc	Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof
ES2664069T3 (es)	2012-06-13	2018-04-18	Merial, Inc.	Vacunas contra BTV y AHSV de genoma reordenado
RU2500817C1 (ru) *	2012-07-19	2013-12-10	Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум")	РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК рВК415, КОДИРУЮЩАЯ ПОЛИПЕПТИД РЕКОМБИНАНТНОГО ТКАНЕВОГО АКТИВАТОРА ПЛАЗМИНОГЕНА ЧЕЛОВЕКА, ЛИНИЯ КЛЕТОК Cricetulus griseus CHO 1F8 - ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ТКАНЕВОГО АКТИВАТОРА ПЛАЗМИНОГЕНА ЧЕЛОВЕКА И СПОСОБ ПОЛУЧЕНИЯ И ВЫДЕЛЕНИЯ ПОЛИПЕПТИДА, ОБЛАДАЮЩЕГО АКТИВНОСТЬЮ ТКАНЕВОГО АКТИВАТОРА ПЛАЗМИНОГЕНА
US10010594B2 (en)	2014-02-11	2018-07-03	University Of Miami	Methods and compositions for transgene expression in a herpesvirus vector system
CA2966191A1 (fr)	2014-11-03	2016-05-12	Merial, Inc.	Procedes d'utilisation de formulations de vaccin par micro-aiguilles pour eliciter une immunite de protection contre le virus de la rage chez les animaux
DK3313864T3 (da)	2015-06-23	2021-11-01	Boehringer Ingelheim Animal Health Usa Inc	Rekombinante virusvektorer indeholdende prrsv minor protein og fremgangsmåder til fremstilling og anvendelse deraf
WO2017031120A1 (fr)	2015-08-20	2017-02-23	Merial, Inc.	Vaccins recombinants contre le fcv et utilisations de ceux-ci
FI3355915T3 (fi)	2015-09-29	2024-01-12	Boehringer Ingelheim Animal Health Usa Inc	Koirien parvoviruksen (CPV) viruksen kaltaisten hiukkasten (VLP) rokotteet ja niiden käytöt
MA42640B1 (fr)	2015-11-23	2021-06-30	Merial Inc	Protéines de fusion de dmdv et e2 et leurs utilisations
TWI760322B (zh)	2016-01-29	2022-04-11	美商百靈佳殷格翰動物保健美國有限公司	重組腺病毒載體裝載之fmdv疫苗及其用途
WO2019155833A1 (fr) *	2018-02-07	2019-08-15	学校法人日本医科大学	Vecteur viral adéno-associé amélioré
KR20210124299A (ko) *	2019-02-04	2021-10-14	더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈	Cln6 폴리뉴클레오티드의 아데노-관련 바이러스 전달

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI86885C (fi) *	1984-04-20	1992-10-26	Genentech Inc	Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
DE3431140A1 (de) *	1984-08-24	1986-03-06	Behringwerke Ag, 3550 Marburg	Enhancer fuer eukaryotische expressionssysteme
IL77081A (en) *	1984-12-04	1999-10-28	Genetics Inst	Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin

1987
- 1987-09-11 GB GB8721424A patent/GB2197321B/en not_active Expired
- 1987-09-11 EP EP87308060A patent/EP0260148A3/fr not_active Withdrawn
- 1987-09-11 DK DK473987A patent/DK175363B1/da not_active IP Right Cessation
- 1987-09-11 NZ NZ22179087A patent/NZ221790A/xx unknown
- 1987-09-11 DE DE19873730599 patent/DE3730599A1/de not_active Withdrawn
- 1987-09-11 AU AU78317/87A patent/AU613316B2/en not_active Expired
- 1987-09-11 IE IE245587A patent/IE872455L/xx unknown
- 1987-09-11 FR FR8712633A patent/FR2603899B1/fr not_active Expired - Lifetime
- 1987-09-12 JP JP62229429A patent/JP2888518B2/ja not_active Expired - Lifetime
1996
- 1996-05-14 JP JP11883796A patent/JP3148121B2/ja not_active Expired - Lifetime
2000
- 2000-04-17 JP JP2000115248A patent/JP2000308497A/ja active Pending

Also Published As

Publication number	Publication date
FR2603899B1 (fr)	1990-07-13
GB2197321B (en)	1990-10-03
EP0260148A3 (fr)	1989-06-07
AU7831787A (en)	1988-05-19
JP2000308497A (ja)	2000-11-07
IE872455L (en)	1988-03-12
JP3148121B2 (ja)	2001-03-19
DK473987D0 (da)	1987-09-11
JP2888518B2 (ja)	1999-05-10
AU613316B2 (en)	1991-08-01
GB2197321A (en)	1988-05-18
EP0260148A2 (fr)	1988-03-16
FR2603899A1 (fr)	1988-03-18
JPH09103296A (ja)	1997-04-22
GB8721424D0 (en)	1987-10-21
DK473987A (da)	1988-03-13
NZ221790A (en)	1990-07-26
DE3730599A1 (de)	1988-07-07
JPS63152986A (ja)	1988-06-25

Legal Events

Date	Code	Title	Description
2007-10-01	PUP	Patent expired

Publication	Publication Date	Title
DK175363B1 (da)	2004-09-13	Fremgangsmåde til kontinuert produktion af et önsket heterologt protein i en eukaryotisk værtcelle, vektor, som tilförer denne evne, og celler transformeret med vektoren
CA1340480C (fr)	1999-04-06	Systeme d'expression transitoire pour la production de proteine recombinantes
Huang et al.	1990	The simian virus 40 small-t intron, present in many common expression vectors, leads to aberrant splicing
Okayama et al.	1983	A cDNA cloning vector that permits expression of cDNA inserts in mammalian cells
Lanford et al.	1995	Nucleotide priming and reverse transcriptase activity of hepatitis B virus polymerase expressed in insect cells
CA1341395C (fr)	2002-10-22	Preparation d'un facteur viii humain fonctionnel
CA1179953A (fr)	1984-12-27	Procede pour l'insertion d'dna dans des cellules eucaryotes pour la production de matieres proteinacees
NZ621527A (en)	2015-10-30	A genetically modified yeast cell and method of production of recombinant protein or polypeptide thereof
CN105492608A (zh)	2016-04-13	CRISPR-Cas9特异性敲除猪PDX1基因的方法及用于特异性靶向PDX1基因的sgRNA
Runkel et al.	1993	Two-codon insertion mutations of the HBx define two separate regions necessary for its trans-activation function
US5914267A (en)	1999-06-22	Pre-mRNA processing enhancer and method for intron-independent gene expression
CN109475619A (zh)	2019-03-15	神经元蜡样脂褐质沉积症的基因治疗
Jameson et al.	1988	Isolation and characterization of the human chorionic gonadotropin β subunit (CGβ) gene cluster: regulation of transcriptionally active CGβ gene by cyclic AMP
Aloni et al.	1985	Attenuation May Regulate Gene Expression in Animal Viruses and Cell
JPH0314840B2 (fr)	1991-02-27
AU612404B2 (en)	1991-07-11	Method for increasing the expression of polypeptides in recombinant cell culture
CA1310601C (fr)	1992-11-24	Vecteurs d'expression
CN117778431B (zh)	2024-10-25	一种用于重组腺相关病毒包装的质粒系统及其应用
Smith et al.	1994	Proximal 2.6 kb of 5′-flanking DNA is insufficient for human renin promoter activity in renin-synthesizing chorio-decidual cells
EP0254315B1 (fr)	1996-03-27	Fragments d'ADN a replication autonome, derivés de cellules de mammifères et ayant une affinité envers les proteines se fixant sur le ADN.
KR100251286B1 (ko)	2000-04-15	혈액응고 제 8인자의 중쇄와 경쇄, 폰 빌리 브란트 인자를 동시에 발현하는 세포주 및 그를 이용한재조합 혈액응고 제 8인자의 제조방법
US4889802A (en)	1989-12-26	Enhanced production of recombinant proteins in myeloma cells
KR101119079B1 (ko)	2012-02-28	인간 혈액응고 제8인자 제조방법
JPH02500947A (ja)	1990-04-05	動物細胞内でのメッセンジャーｒｎａの安定化
Bruening	1992	Restriction of virus infection by plants. Final report, July 1, 1987--June 30, 1992